MDCO : Analysis & Opinions

  1. The Medicines Co. Gets CHMP Recommendation for 3 Drugs - Analyst ...

    January 27, 2015
    The Medicines Company (MDCO) announced that the CHMP has issued positive opinions regarding the marketing authorization for ...
  2. Synthetic Biologics Commences Phase Ib Study on SYN-004 - Analyst ...

    December 31, 2014
    Synthetic Biologics, Inc. (SYN) announced the commencement and dosing of the first patient in a phase Ib study on its oral ...
  3. Repros Gains on Positive Updates on the Status of Androxal - ...

    December 30, 2014
    Repros Therapeutics (RPRX) announced the submission of a complete response to the guidance regarding the expected NDA submission ...
  4. Vertex Pharmaceuticals' Kalydeco Label Expanded in the U.S. - ...

    December 30, 2014
    Vertex Pharmaceuticals Incorporated (VRTX) received good news when the FDA approved its supplemental new drug application ...
  5. Ignyta's Lead Oncology Candidate Gets Orphan Drug Status - Analyst ...

    December 30, 2014
    Ignyta, Inc.'s (RXDX) lead candidate, entrectinib (RXDX-101), received orphan drug status and rare pediatric disease designation ...
  6. Synthetic Biologics Unveils Top-Line Safety Data on SYN-004 - ...

    December 29, 2014
    Synthetic Biologics, Inc. (SYN) announced positive results from the first safety and tolerability review in a phase Ia study ...
  7. Kite Pharma Files IND for Non-Hodgkin Lymphoma Drug - Analyst ...

    December 29, 2014
    Kite Pharma, Inc. (KITE) submitted an investigational new drug application to the FDA for KTE-C19 for refractory aggressive ...
  8. BioLineRx Out-Licences Skin Lesion Treatment Candidate - Analyst ...

    December 26, 2014
    BioLineRx (BLRX) out-licenced BL-5010 in Europe, Australia and additional countries to Omega Pharma.
  9. MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst ...

    December 23, 2014
    MacroGenics, Inc. (MGNX) entered into a collaboration and license agreement with Johnson & Johnson for the development ...
  10. Alnylam Provides Pipeline Update, Growth Strategy - Analyst Blog

    December 15, 2014
    Alnylam (ALNY) announced a strategy for developing its RNAi therapeutics in three strategic therapeutic areas (STArs): genetic ...
  11. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
Trading Center